Literature DB >> 20010925

The impact of thiopurines on the risk of surgical recurrence in patients with Crohn's disease after first intestinal surgery.

Pavol Papay1, Walter Reinisch, Elien Ho, Cornelia Gratzer, Donata Lissner, Harald Herkner, Stefan Riss, Clemens Dejaco, Wolfgang Miehsler, Harald Vogelsang, Gottfried Novacek.   

Abstract

OBJECTIVES: Smoking and a lack of immunosuppressive (IS) therapy are considered risk factors for intestinal surgery in Crohn's disease (CD). Good evidence for the latter is lacking. The objective of this study was to evaluate the impact of thiopurine treatment on surgical recurrence in patients after first intestinal resection for CD and its possible interaction with smoking.
METHODS: Data on 326 patients after first intestinal resection were retrieved retrospectively, and subjects were grouped according to their postoperative exposure to thiopurines. Treatment with either azathioprine (AZA) or 6-mercaptopurine (6-MP) was recorded on 161 patients (49%). Smoking status was assessed by directly contacting the patients.
RESULTS: Surgical recurrence occurred in 151/326 (46.3%) patients after a median time of 71 (range 3-265) months. Cox regression revealed a significant reduction of re-operation rate in patients treated with AZA/6-MP for > or = 36 months as compared with patients treated for 3-35 months, for less than 3 months, and to those without postoperative treatment with AZA/6-MP (P=0.004). Cox regression analysis revealed treatment with thiopurines for > or = 36 months (hazard ratio (HR) 0.41; 95% confidence interval (CI) 0.23-0.76, P=0.004) and smoking (HR 1.6; 95% CI 1.14-2.4, P=0.008) as independent predictors for surgical recurrence. Furthermore, longer duration of disease tended to be protective (HR 0.99; 95% CI 0.99-1.0, P=0.067).
CONCLUSIONS: Long-term maintenance treatment with AZA/6-MP reduces the risk of surgical recurrence in patients with CD. We also identified smoking as a risk factor for surgical recurrence.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20010925     DOI: 10.1038/ajg.2009.673

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  20 in total

Review 1.  Management of Crohn's disease in smokers: is an alternative approach necessary?

Authors:  Pilar Nos; Eugeni Domènech
Journal:  World J Gastroenterol       Date:  2011-08-21       Impact factor: 5.742

2.  Surgical recurrence after primary ileocolic resection for Crohn's disease.

Authors:  S Riss; I Schuster; P Papay; F Herbst; M Mittlböck; P Chitsabesan; A Stift
Journal:  Tech Coloproctol       Date:  2013-08-28       Impact factor: 3.781

Review 3.  Surgical recurrence in Crohn's disease: Are we getting better?

Authors:  Ivan Kristo; Anton Stift; Michael Bergmann; Stefan Riss
Journal:  World J Gastroenterol       Date:  2015-05-28       Impact factor: 5.742

Review 4.  Impact of environmental and dietary factors on the course of inflammatory bowel disease.

Authors:  Eduard Cabré; Eugeni Domènech
Journal:  World J Gastroenterol       Date:  2012-08-07       Impact factor: 5.742

Review 5.  State-of-the-art medical prevention of postoperative recurrence of Crohn's disease.

Authors:  Dario Sorrentino
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-05-07       Impact factor: 46.802

Review 6.  Current status of thiopurine analogues in the treatment in Crohn's disease.

Authors:  Peter Laszlo Lakatos; Lajos S Kiss
Journal:  World J Gastroenterol       Date:  2011-10-21       Impact factor: 5.742

7.  Postoperative Effects of Thiopurines in Patients with Intestinal Behçet's Disease.

Authors:  Hye Won Lee; Jae Hee Cheon; Hyun Jung Lee; Soo Jung Park; Sung Pil Hong; Tae Il Kim; Won Ho Kim
Journal:  Dig Dis Sci       Date:  2015-07-22       Impact factor: 3.199

8.  Perioperative Blood Transfusion and Postoperative Outcome in Patients with Crohn's Disease Undergoing Primary Ileocolonic Resection in the "Biological Era".

Authors:  Yi Li; Luca Stocchi; Yuanyi Rui; Ganglei Liu; Emre Gorgun; Feza H Remzi; Bo Shen
Journal:  J Gastrointest Surg       Date:  2015-08-19       Impact factor: 3.452

Review 9.  What is left when anti-tumour necrosis factor therapy in inflammatory bowel diseases fails?

Authors:  Ian C Lawrance
Journal:  World J Gastroenterol       Date:  2014-02-07       Impact factor: 5.742

Review 10.  Prevention of post-operative recurrence of Crohn's disease.

Authors:  Byron Philip Vaughn; Alan Colm Moss
Journal:  World J Gastroenterol       Date:  2014-02-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.